Protagonist Therapeutics Balance Sheet
NASDAQ: PTGXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Protagonist Therapeutics financial position
At the end of fiscal 2025, Protagonist Therapeutics reported total assets of $668.2 million, down 10.3% from a year earlier against total liabilities of $53.5 million. Shareholders' equity stood at $614.7 million, or 92.0% of assets. The company held $128.4 million in cash and equivalents.
The current ratio (current assets divided by current liabilities) was 12.71, meaning short-term assets cover obligations due within a year.
Summary generated from market data by MetaCap's automated system. Methodology
Protagonist Therapeutics balance sheet (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 | FY 20182018-12-31 | FY 20172017-12-31 | FY 20162016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | 128.39M | 97.25M | 186.73M | 125.74M | 123.67M | 117.36M | 33.01M | 82.23M | 106.03M | 21.08M |
| Short-Term Investments | 438.97M | 321.66M | 154.89M | 111.61M | 203.24M | 188.45M | 100.01M | 46.62M | 37.97M | 56.52M |
| Total Current Assets | 577.57M | 591.64M | 355.58M | 243.08M | 340.74M | 315.61M | 145.31M | 137.50M | 150.95M | 83.24M |
| Property, Plant & Equipment | 3.86M | 3.19M | 1.20M | 1.56M | 1.80M | 1.46M | 1.68M | 861.00K | 879.00K | 562.00K |
| Long-Term Investments | 78.64M | 140.25M | — | 0 | — | 2.00M | — | — | — | — |
| Total Assets | 668.19M | 744.73M | 357.95M | 247.93M | 347.69M | 324.47M | 154.92M | 139.47M | 163.73M | 93.99M |
| Accounts Payable | 5.34M | 1.61M | 772.00K | 3.64M | 1.60M | 3.08M | 2.79M | 5.71M | 1.26M | 1.16M |
| Total Current Liabilities | 45.44M | 47.40M | 21.27M | 31.18M | 44.02M | 40.24M | 35.41M | 26.16M | 42.55M | 6.43M |
| Long-Term Debt | — | — | — | — | — | — | 9.79M | — | — | — |
| Total Liabilities | 53.48M | 69.43M | 21.27M | 32.32M | 47.67M | 44.86M | 74.95M | 26.96M | 43.10M | 6.43M |
| Shareholders' Equity | 614.71M | 675.29M | 336.68M | 215.61M | 300.02M | 279.61M | 79.96M | 112.52M | 120.63M | 87.56M |
| Retained Earnings | -470.67M | -340.52M | -615.71M | -536.75M | -409.36M | -283.81M | -217.66M | -140.47M | -101.55M | -64.59M |
| Total Debt | — | — | — | — | — | — | 9.79M | — | — | — |
| Net Cash (Debt) | 567.36M | 418.91M | 341.62M | 237.35M | 326.90M | 305.81M | 123.22M | 128.85M | 144.00M | 77.60M |
| Shares Outstanding | 62.58M | 61.04M | 57.71M | 49.34M | 47.84M | 43.75M | 27.22M | 23.19M | 21.09M | 16.72M |
This table shows 10 annual periods of Protagonist Therapeutics's balance sheet, from FY 2025 back to FY 2016, across 15 line items including cash & equivalents, short-term investments, total current assets. Values in USD; B = billions, M = millions. Fiscal periods follow PTGX's reporting calendar. What is a balance sheet?